Posts in category The Endpoint

The Endpoint

The outlook for Amgen

Once oral dialysis drugs like Amgen’s Sensipar, used to treat hyperparathyroidism, are included in the dialysis payment bundle, it is unlikely that the inevitable drop in sales will match what the biotech firm has seen from its anemia drugs.

The Endpoint

News from the Kidney Community

This new bi-weekly summary is intended to highlight the important stories from and about the kidney care community and offer a place to analyze and discuss them, as well as dive deeper into some of the issues we are covering on our website and in the pages of our magazine.